Compile Data Set for Download or QSAR
Report error Found 46 Enz. Inhib. hit(s) with all data for entry = 11792
TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648408(US11352350, Compound I-41)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648395(US11352350, Compound I-30 | US11352350, Compound I...)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648399(US11352350, Compound I-32)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648401(US11352350, Compound I-34)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648402(US11352350, Compound I-35)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648403(US11352350, Compound I-36)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648404(US11352350, Compound I-37)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648405(US11352350, Compound I-38)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648407(US11352350, Compound I-40)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648380(US11352350, Compound I-2)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648409(US11352350, Compound I-42)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648411(US11352350, Compound I-45)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648414(US11352350, Compound I-48)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648415(US11352350, Compound I-58)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648416(US11352350, Compound I-59)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648418(US11352350, Compound I-62)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648419(US11352350, Compound I-65)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648394(US11352350, Compound I-27)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648393(US11352350, Compound I-18)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648392(US11352350, Compound I-17)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648391(US11352350, Compound I-16)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648381(US11352350, Compound I-3)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648389(US11352350, Compound I-11)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648388(US11352350, Compound I-10)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648387(US11352350, Compound I-9)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648384(US11352350, Compound I-6)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648386(US11352350, Compound I-8)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648385(US11352350, Compound I-7)
Affinity DataIC50: 50nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648398(US11352350, Compound I-31)
Affinity DataIC50: 75nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648422(US11352350, Compound I-76)
Affinity DataIC50: 75nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648421(US11352350, Compound I-75)
Affinity DataIC50: 75nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648420(US11352350, Compound I-67)
Affinity DataIC50: 75nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648417(US11352350, Compound I-61)
Affinity DataIC50: 75nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648410(US11352350, Compound I-43)
Affinity DataIC50: 75nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648406(US11352350, Compound I-39)
Affinity DataIC50: 75nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648395(US11352350, Compound I-30 | US11352350, Compound I...)
Affinity DataIC50: 75nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648383(US11352350, Compound I-5)
Affinity DataIC50: 300nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648378(US11352350, Compound I-1)
Affinity DataIC50: 300nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648424(US11352350, Compound I-92)
Affinity DataIC50: 300nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648425(US11352350, Compound I-94)
Affinity DataIC50: 300nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648413(US11352350, Compound I-47)
Affinity DataIC50: 750nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648412(US11352350, Compound I-46)
Affinity DataIC50: 750nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648390(US11352350, Compound I-12)
Affinity DataIC50: 750nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648400(US11352350, Compound I-33)
Affinity DataIC50: 750nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648396(US11352350, Compound I-29)
Affinity DataIC50: 750nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM648423(US11352350, Compound I-81)
Affinity DataIC50: 1.00E+3nMAssay Description:Whole blood was collected in heparinized tubes and plated on the same day as draw (day 0). Whole blood was aliquoted into deep well plates. Compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2024
Entry Details
Go to US Patent